title: New medications for use in patients with rheumatoid arthritis.
abstract: BACKGROUND
  Several new medications have become available to physicians for the treatment of patients with rheumatoid arthritis (RA).
  
  
  OBJECTIVE
  To familiarize the reader with these new medications, including their benefits and side effects.
  
  
  METHODS
  Data sources include published articles regarding the use of these medications. Study selection includes available information obtained from an online literature search (Mayo Search) regarding these agents, with additional information from the manufactures and our pharmacy.
  
  
  CONCLUSIONS
  The results of this review indicate that leftunomide (Arava) and etanercept (Enbrel) are useful new agents for treatment of patients with rheumatoid arthritis.
authors.affiliation: Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: K G
authors.initials: KG
authors.lastname: Moder
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept; D005252:Fees, Pharmaceutical; D006801:Humans; D007074:Immunoglobulin G / Q000191:economics / Q000627:therapeutic use; D007555:Isoxazoles / Q000191:economics / Q000627:therapeutic use; D000077339:Leflunomide; D008727:Methotrexate / Q000191:economics / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D007555:Isoxazoles; D018124:Receptors, Tumor Necrosis Factor; D000077339:Leflunomide; D000068800:Etanercept; D008727:Methotrexate